CYAD News and Press, Celyad SA From 01/19/23

Palm Beach, FL – January 19, 2023 – FinancialNewsMedia.com News Commentary – Gamma Delta T Cell Therapy represents one of the most promising T Cell therapies in clinical development. The introduction of T cell-based immunotherapy has greatly revolutionized the par...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday! Moving stocks this morning are heavy pre-market trading...

3 Trends to Watch For in 2023 to Make Money With Penny Stocks Penny stocks have always been a popular investment option for those looking to make a quick profit, but this year, there are a few trends that are helping investors make even more money. One of the biggest trends is the use of soci...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off Tuesday with a look at the biggest pre-market stock movers traders will want to keep an eye on! Moving stocks this morning are merger plans, clinical trial...

Celyad Oncology ( NASDAQ: CYAD ) said it will discontinue the development of its multiple myeloma therapy CYAD-211 as part of a strategic and financial review. The Belgium-based company said that, under its new business strategy, it has compiled a broad IP estate that co...

MONT-SAINT-GUIBERT, Belgium, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today provi...

Company continues to transition business focus to monetizing unique cell therapy intellectual property and prioritizing R&D discovery Clinical updates expected by end of year for the Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CY...

Ncardia's unit Cellistic is acquiring Celyad Oncology's ( NASDAQ: CYAD ) cell therapy manufacturing facility and related personnel (the manufacturing business unit) in Mont-Saint-Guibert, Belgium for €6M. The transaction is subject to conditions and is expe...

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announce...

Euro Tech Holdings Company ( CLWT ) +39% . SilverSun Technologies ( SSNT ) +28% . Aethlon Medical ( AEMD ) +19% CEO Chuck Fisher on Q1 2023 Results - Earnings Call Transcript. The Trade Desk ( TTD ) +16% Inc. 2023 Q2 - Results - Earnings C...